Progranulin modulates zebrafish motoneuron development in vivo and rescues truncation defects associated with knockdown of Survival motor neuron 1 by Chitramuthu, Babykumari P et al.
RESEARCH ARTICLE Open Access
Progranulin modulates zebrafish motoneuron
development in vivo and rescues truncation
defects associated with knockdown of Survival
motor neuron 1
Babykumari P Chitramuthu
1,2, David C Baranowski
2, Denis G Kay
2, Andrew Bateman
1, Hugh PJ Bennett
1*
Abstract
Background: Progranulin (PGRN) encoded by the GRN gene, is a secreted glycoprotein growth factor that has
been implicated in many physiological and pathophysiological processes. PGRN haploinsufficiency caused by
autosomal dominant mutations within the GRN gene leads to progressive neuronal atrophy in the form of
frontotemporal lobar degeneration (FTLD). This form of the disease is associated with neuronal inclusions that bear
the ubiquitinated TAR DNA Binding Protein-43 (TDP-43) molecular signature (FTLD-U). The neurotrophic properties
of PGRN in vitro have recently been reported but the role of PGRN in neurons is not well understood. Here we
document the neuronal expression and functions of PGRN in spinal cord motoneuron (MN) maturation and
branching in vivo using zebrafish, a well established model of vertebrate embryonic development.
Results: Whole-mount in situ hybridization and immunohistochemical analyses of zebrafish embryos revealed that
zfPGRN-A is expressed within the peripheral and central nervous systems including the caudal primary (CaP) MNs
within the spinal cord. Knockdown of zfPGRN-A mRNA translation mediated by antisense morpholino
oligonucleotides disrupted normal CaP MN development resulting in both truncated MNs and inappropriate early
branching. Ectopic over-expression of zfPGRN-A mRNA resulted in increased MN branching and rescued the
truncation defects brought about by knockdown of zfPGRN-A expression. The ability of PGRN to interact with
established MN developmental pathways was tested. PGRN over-expression was found to reverse the truncation
defect resulting from knockdown of Survival of motor neuron 1 (smn1). This is involved in small ribonucleoprotein
biogenesis RNA processing, mutations of which cause Spinal Muscular Atrophy (SMA) in humans. It did not reverse
the MN defects caused by interfering with the neuronal guidance pathway by knockdown of expression of NRP-1,
a semaphorin co-receptor.
Conclusions: Expression of PGRN within MNs and the observed phenotypes resulting from mRNA knockdown and
over-expression are consistent with a role in the regulation of spinal cord MN development and branching. This
study presents the first in vivo demonstration of the neurotrophic properties of PGRN and suggests possible future
therapeutic applications in the treatment of neurodegenerative diseases.
Background
Progranulin (PGRN) (also called granulin-epithelin pre-
cursor, PC-derived growth factor, transforming growth
factor-e, acrogranin or proepithelin) is a secreted
glycoprotein that contains multiple linear repeats of the
disulfide-rich granulin motif [1]. PGRN is implicated in
numerous physiological and disease processes [2]
including early development of the embryo [3-6], wound
healing [7], inflammation [8,9], chondrogenesis [10] and
cancer (reviewed in [2]). While it has long been known
that PGRN is expressed in neurons of the adult and
developing murine nervous system [11], roles for PGRN
in the CNS have only recently emerged. GRN mutations
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frontotemporal lobar degeneration associated with ubi-
quitin inclusions (FTLD-U). FTLD-U belongs to the
subset of neurodegenerative diseases that are character-
ized histologically by ubiquitin-positive cytoplasmic and
intranuclear neuronal inclusions containing the TAR
DNA binding protein, TDP-43 [12,13]. Familial FTLD is
heterogeneous and in addition to GRN mutations, also
arise from mutations of MAPT, the gene encoding the
Tau protein. However, this variant differs histologically
from FTLD-U in displaying Tau aggregation but lacking
ubiquitinated TDP-43 inclusions [14]. To date 68 patho-
genic autosomal dominant mutations have been
reported to occur in the GRN gene [15]. The majority
are nonsense mutations that lead to the introduction of
premature stop codons resulting in elimination of the
nascent PGRN mRNA through the process of nonsense
mediated decay [14,16]. FTLD-U usually manifests initi-
ally either as behavioral or linguistic defects [17-19], and
while it is predominantly an early onset form of demen-
tia, the age of inception is highly variable ranging from
35-85 years [20]. This highly variable age-dependent
penetrance suggests that the actions of PGRN are influ-
enced by other gene products and possibly environmen-
tal factors. FTLD-U is invariably fatal and no effective
treatment exists at present [21].
Many neurodegenerative conditions are associated
with the accumulation of toxic protein aggregates
including amyloid, tau-fibrils, synuclein and huntingtin
[22,23]. The role of PGRN in FTLD-U is different in
that the primary cause of the disease is partial loss of
PGRN protein levels [19]. This results ultimately in neu-
ronal cell death although the details of how this occurs
are not well understood. While Grn-deficient mice do
not appear to develop overt FTLD, recent studies of
knockout mice emphasize how vulnerable neuronal tis-
sue is to low PGRN levels. The sensitivity of hippocam-
pal neurons to hypoxia-induced cell death is increased
[24] and they exhibit enhanced aggressiveness and anxi-
ety consistent with alterations in brain development
[25]. Furthermore, PGRN has been implicated in the
male-specific differentiation of the murine hypothalamus
[26]. PGRN deficient mice display an exaggerated
inflammatory response upon exposure to Listeria mono-
cytogenes and chronic infection over time leads to
greater activation of microglia and astrocytes and resul-
tant neuronal damage [24]. Progranulin deficient mice
display a range of behavioural deficits and progressive
neuropathological defects [27]. Knockout mice also dis-
play increased neuronal lipofuscinosis and ubiquitination
as they age suggesting a critical role for PGRN as a
long-term neuronal survival factor [28]. We, and others,
have shown that PGRN is neuroprotective in vitro
[29,30], but little is currently known about how PGRN
affects neuronal survival and development in vivo.T h i s
is clearly an important question given the devastating
clinical effects of partial loss of PGRN expression in
FTLD patients. Here we employed the zebrafish animal
model to investigate this issue.
The zebrafish (Danio rerio) has emerged as a powerful
tool to study early developmental events, to define gene
function and to model human disease [31]. Unlike the
mammalian genome that contains only a single GRN
gene, the zebrafish possesses four distinct GRN genes.
Two of these genes, namely grna and grnb resemble
mammalian GRN in possessing multiple tandem repeats
of the GRN motif. Syntenic conservation of gene locali-
zation suggests that of these, grna is the true orthologue
of the human GRN gene [32,33] and was therefore the
major focus of this study. In previous studies we have
identified central and spinal cord motoneurons as
among the most highly PGRN-expressing cells in the
murine nervous system and demonstrated a cytoprotec-
tive action for PGRN on MN-like cells in vitro [30].
This prompted an examination of PGRN in MN devel-
opment in zebrafish.
During the first 24 hours post-fertilisation (hpf) in
zebrafish primary caudal (CaP), mid (MiP), and rostral
(RoP) motor neurons initially share a common pathway.
This is the developmental period encompassed in our
studies. Normal CaP neurons rarely branch before the
horizontal myoseptum (HM) [34], an assembly of mus-
cle pioneer cells which serves as a transient target for
developing primary motoneurons prior to the develop-
ment of axonal projections that extend toward target
populations of muscles cells. The CaP neurons develop
first and extend ventrally beyond the horizontal myo-
septum where branching promotes functional contact
within the myotome. The development of CaP neurons
is a well characterized experimental model to study
mechanisms that regulate MN axonal development and
projection [34]. Axonal projection and branching are
readily visualized in embryo whole-mounts and anti-
sense mRNA knockdown of factors that specifically dis-
rupt CaP development have been reported [35,36].
Growth cone guidance is provided by secreted factors
including semaphorins, netrins and ephrins [37]. MN
differentiation and survival is also influenced by mor-
phogens and other humoral factors including IGF [38],
Wnt and Shh signaling [39]. Our results suggest
t h a tP G R Nm a ya l s op l a yar o l ei nr e g u l a t i n gt h e s e
processes.
Results
Zebrafish progranulin-A is expressed within the Central
Nervous System (CNS) and Peripheral Nervous System (PNS)
In our initial studies of zebrafish PGRN (zfPGRN)
expression [32] we demonstrated that there is general
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tectum during the first 24 hpf. Given the high expres-
sion of PGRN in murine MNs we investigated
zfPGRN-A expression using whole mount in situ
hybridization at 27 hpf with specific emphasis on
expression within MNs (Figure 1, Panels A and C).
Expression of zfPGRN-A was detected during neural
development in the retina, hindbrain, tectum, spinal
cord and caudal primary (CaP) motoneuron (MNs). At
27 hpf zfPGRN-A expression was also detected in the
somite boundaries, a potential source of factors influ-
encing MN development (Figure 1, Panel C and D).
A similar tissue-distribution pattern was observed for
immunoreactive zfPGRN-A using whole mount immu-
nofluorescence (Figure 2, Panels A, D, C and F). Con-
trol experiments where the primary antibody is
replaced with normal calf serum to eliminate the pos-
sibility of non-specific staining did not produce an
immunoreactive signal (data not shown). The expres-
sion of zfPGRN-A within the MNs was further con-
firmed by the co-localization with znp1, a marker for
MNs (Figure 2, Panels B, C, E and F). These observa-
tions are consistent with murine neural expression of
PGRN during development [11].
zfPGRN-A knockdown results in disrupted development
of multiple neural structures
Antisense morpholino (MO) technology was employed
to investigate the function of zfPGRN-A in neural devel-
opment by knocking down gene expression by injection
oligonucleotides into zebrafish embryos at the 1 to 2
cell stage. Two independent zfPGRN-A MO were
employed to inhibit zfPGRN-A translation directed
either against the zfPGRN-A ATG (designated as MO1)
or the 5′UTR (designated as MO2). Titration of the con-
centration of injected zfPGRN-a MO2 against zfPGRN-
A levels demonstrated that 10 ng/embryo of the
zfPGRN-A MO effectively decreased zfPGRN-A transla-
tion (Figure 3, Panel A) without affecting the expression
of the orthologue zfPGRN-B. Injection of the equivalent
amount of a 5 base-pair mismatch control morpholino
(mm) or an equivalent scrambled sequence (scr)
resulted in little or no decrease in zfPGRN-A expression
(Figure 3, Panel A). Co-injection of zfPGRN-A-MO with
zfPGRN-A mRNA restored zfPGRN-A protein levels
(Figure 3, Panel B). The efficacy of translation from
injected mRNA was confirmed by injection of hPGRN
mRNA or control green fluorescent protein (gfp) mRNA
which were shown by Western blot to be translated into
Figure 1 Zebrafish PGRN-A in situ expression in the Spinal cord and MNs. Lateral view of 24-27 hpf embryos revealed zfPGRN-A expression
within the Peripheral and Central Nervous systems. In the head region, zfPGRN-A is expressed at 24 hpf in the head and brain particularly in the
tectum, midbrain-hindbrain boundary and eye (Panel A). The sense control displayed minimal signal (Panel B). In addition zfPGRN-A is also
expressed at 27 hpf in the somite boundaries (Panel C). At greater magnification of the boxed area in Panel C, zfPGRN-A expression in the
somite boundaries is more apparent together with expression in the motoneurons (Panel D). Abbreviations: T: Tectum; E:Eye, MHB:Mid-Brain,
Hind-brain Boundary; SB:Somite Boundary, MN:Motoneurons; ICM: Intermediate cell mass. Images were captured at 6X magnification and the
hatched box was further subject to 2-3X Zoom
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was observed throughout the embryo (Additional
File 1). Embryonic injection of 10 ng zfPGRN-A MO
resulted in disrupted development of multiple neural
structures at 36 hpf (assessed by islet-1 expression) that
was partially rescued by co-injection with zfPGRN-A
mRNA (Figure 4). The expression pattern, knockdown
and rescue experiments suggest roles for PGRN in CNS
development.
Knockdown of PGRN-A expression generates defects in
motoneuron development
We visualized the development of the CaP neurons in
whole mount embryos at 27 hpf by immunostaining
using the znp1 monoclonal antibody that labels pri-
mary MNs (Figure 5). Data sets are presented as lat-
eral images of developing primary MNs found within
three or four somatic hemisegments of the 12-13
found in each developing embryo. This occurs on
both sides of the body and accounts for the apparent
image duplication seen with such images. This can be
seen for example in several of the panels shown in
Figure 5. CaP MNs were scored for truncation and
aberrant branching. Both wild type and embryos
injected with control morpholino (MO) show normal
CaP MN development (Figure 5, Panels A and B;
Figure 6). Knockdown of zfPGRN-A caused truncation
and frequent premature branching of CaP MNs proxi-
mal to the HM at 27 hpf (Figure 5, Panels E and F).
The incidence of both truncated and premature
branching of CaP motoneurons generated by PGRN-A
knockdown is significant when compared to embryos
injected with control MO or wild type embryos
(Figure 6). To evaluate whether reduction of zfPGRN-
B expression disrupts the formation of neural struc-
tures and motoneuron development we knocked down
zfPGRN-B using an MO directed against the UTR
region of PGRN-B. The depletion of PGRN-B pro-
duced a severe phenotype notably including a reduc-
tion in head size seen at 24 hpf (data not shown).
This is consistent with the high levels of mRNA pro-
vided maternally to the newly fertilised egg and the
extensive expression of zfPGRN-B found throughout
larval brain. These observations make it difficult to
analyze the possible role of zfPGRN-B in motoneuron
development at this time.
Figure 2 Colocalization of zfPGRN-A and znp1 immunoreactivity in Primary motor neurons at 27 hpf. Lateral views (anterior- left; dorsal-
top) of whole-mount embryos labelled with zfPGRN-A (A, D) and znp1 mAb (B, E) at 27 hpf. Embryos show zfPGRN-A expression in the developing
eye, tectum and hindbrain (A); Spinal Cord, Somite boundaries and motor neurons (D); znp1 expression in the eye, hindbrain, Spinal Cord and
motor neurons (B and E). Merged images show co-localization of zfPGRN-A and znp1 (C, F). Abbreviations: T, Tectum; E, Eye; MHB, Mid-Brain
Hindbrain Boundary; SB, Somite boundary; MN, Motoneurons.; SC, Spinal cord. Images were captured at 20 × magnification. Scale Bar = 50 μm.
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the truncation defects resulting from knockdown of
PGRN-A expression
Ectopic expression of either zfPGRN-A mRNA or
hPGRN mRNA increased the incidence of branching
(Figure 5, Panels C and D; Figure 6) without causing
truncation defects. Co-injection of either zfPGRN-A
mRNA or hPGRN mRNA together with zfPGRN-A
MO1 or 2 significantly reduced the incidence of trun-
cated neurons suggesting that zfPGRN-A is necessary
for normal CaP MN development (Figure 5, Panels G
and H; Figure 6, Panel A). In addition, the co-injection
of either zfPGRN-A mRNA or hPGRN mRNA with
zfPGRN-A MO 1 or 2 increased the incidence of early
and late branching when compared to MO injection.
These studies suggest that zfPGRN-A promotes neuro-
nal outgrowth in vivo (Figure 5, Panels C, D, G and H;
Figure 6, Panel B). The phenotypes were validated in
each category with 3 independent experiments with
sample sizes of at least 20 (WT, Control, PGRN MO1,
PGRN MO2, PGRN MO2 plus PGRN-A mRNA and
PGRN MO2 plus hPGRN mRNA).
Knockdown of zfPGRN-A impedes the avoidance swim
response
To determine whether the motoneuron defects observed
when zfPGRN-A expression was depleted were manifest
as functional defects we tested the embryo touch
response and avoidance swimming behaviour 48 hrs post
injection. While the touch response is unaltered, PGRN-
A deficient embryos show a marked swimming defect.
Embryos do not show the strong avoidance swimming
phenotype typical of wild-type embryos. At 72 hrs post
injection the motility of zfPGRN-A deficient embryos is
further reduced and that this defect worsens progres-
sively beyond 48 hpf. This suggests that while there is no
major sensory deficit there is a motor deficit possibly due
to defective innervation of MNs in the PGRN-A knock-
down embryos (Additional File 2, Supplementary Table
S1; Additional Files 3, 4, 5, 6, Supplementary Videos 1-
4;). The defect was rescued by co-injection of either
zfPGRN-A or hPGRN-A together with zfPGRN-A MO1
(Additional File 2, Supplementary Table S1; Additional
Files 7 and 8, Supplementary Videos 5 and 6). The major-
ity of the embryos over-expressing either zfPGRN-A or
hPGRN-A show the strong avoidance swimming pheno-
type typical of wild-type embryos (Additional File 2, Sup-
plementary Table S1; Additional Files 9 and 10,
Supplementary Videos 7 and 8).
zfPGRN-A reverses the smn1 knockdown phenotype
in vivo
To determine whether zfPGRN-A modulates the actions
of factors known to modify MN developmental fate, we
investigated the ability of zfPGRN-A to rescue defects in
previously characterised motoneuron developmental
pathways. Two such pathways were chosen; knockdown
of Survival of Motorneuron-1 SMN1,ap r o t e i nw i t h
important roles in spliceosomal small nuclear ribonu-
cleoprotein biogenesis and axon outgrowth [40] and
Neuropilin 1a, a semaphorin co-receptor that interacts
with other mediators of the semaphorin pathway to reg-
u l a t ea x o n a lg u i d a n c e[ 41]. Mutations in human SMN1
are known to cause spinal muscular atrophy (SMA)
[42], the most common genetic cause of early lethality
in children and abnormal variants have been implicated
in sporadic ALS [43]. MO-induced knockdown of SMN
resulted in truncated and aberrantly branched CaP neu-
rons that, as reported previously, reproduce aspects of
human SMA [35], (Figure 7, Panels A and B). Co-injec-
tion of the smn1 MO with zfPGRN-A mRNA reversed
the truncation defects. Branching increased relative to
the results obtained with MO alone (Figure 7 Panel C).
Phenotypes were validated using at least 50 embryos in
each category and the data is presented as histograms in
Figure 8, Panels A and B. To determine the rescue effect
of PGRN in reversing motoneuron defects due to smn1
Figure 3 zfPGRN-A knockdown, rescue and over-expression. (A)
Dose-dependent efficacy of morpholino (MO2) targeting the 5’ UTR
of zfPGRN-A was assessed by Western blot analysis in comparison to
its co-orthologue zfPGRN-B and actin. zfPGRN-A and B are
represented by single bands of approximately 55 and 30 kDa,
respectively. The Western blot analysis of MO knockdown efficacy is
a representative of three independent injection sets. (B) Western
blot analysis of protein extracts from embryos injected with 10 ng
of zfPGRN-A MO1, 10 ng of zfPGRN-A MO2, zfPGRN-A-MO2 together
with zfPGRN-A mRNA. Injection of 10 ng/embryo of the zfPGRN-A
MO1 and MO2 effectively decreased zfPGRN-A translation, zfPGRN-
A-MO together with mRNA resulted in normal zfPGRN-A translation.
(C) Control experiments showing the results of the injection of
100pg hPGRN mRNA and 1ng gfp mRNA demonstrating translation
into protein for both.
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touch response and avoidance swimming behaviour 48
hrs post injection. While the smn1 knockdown embryos
do not show the strong avoidance swimming phenotype
typical of wild-type larvae, the embryos co-injected with
either zfPGRN-A or hPGRN show an improved avoid-
ance swimming phenotype when compared to that
resulting from knockdown of smn1 (Additional File 2,
Supplementary Table S1; Additional Files 11, 12, 13,
Supplementary Videos 9-11). It is also interesting to
note that about 85 percent of embryos co-injected with
either zfPGRN-A or hPGRN together with smn1 MO
survived 24 hrs post injection whereas the smn1 knock-
down embryos showed only 50 percent survival 24 hrs
post injection. These studies suggest that PGRN is pro-
tective against the MN truncation observed in a model
of SMA and confirms that PGRN is a potent stimulator
of neuronal branching in vivo. As reported previously
[36] MO-induced knockdown of NRP-1a mRNA causes
multiple exits, branching and displaced MNs but
resulted in no truncation defects (Figure 9, Panels A
and B). Co-injection of NRP1a MO with zfPGRN-A
mRNA increased branching versus NRP-1a MO alone
(Figure 9, Panel C) but did not prevent multiple exits or
displaced neurons.
Discussion
While it is known that PGRN is cytoprotective for neu-
rons in vitro [29,30], and its partial loss results in neuro-
degeneration in FTLD-U [14,16] little is known how
PGRN affects neurons in vivo. Here we employed zebra-
fish to investigate this important question. The zebrafish
harbors an extended PGRN gene family with four dis-
tinct members [32]. Both grna and grnb encode precur-
sors structurally homologous to the single human gene
and are expressed within the CNS. High maternal
expression of grnb was observed. In addition, grna is
also expressed maternally but at much lower levels and
this expression increases over time [32]. The other GRN
genes grn1 and grn2 are expressed weakly at 48 hpf and
only become strongly expressed in the intestine and
pharyngeal region at 3 dpf and beyond [32]. We focused
our study on grna because (1) it is true orthologue of
the single human gene (2) it is expressed within the
CNS and (3) the lower level of maternal expression may
result in less severe phenotypes when expression is
knocked down. We observed that the expression of grna
occurs during neural development in the retina, hind-
brain, tectum (Figure 1 and 2) and that depletion of
zfPGRN-A results in a general disruption of neuronal
development as assessed by the islet-1 marker during
the first 24 hpf and beyond (Figure 4, and data not
shown). Following our finding that mouse motor neu-
rons express PGRN [30] we examined the expression of
zfPGRN-A at both mRNA and protein levels to deter-
mine whether grna is expressed within zebrafish MNs.
Both caudal primary (CaP) motoneurons (MNs) and
somatic boundaries express zfPGRN-A during this per-
iod (Figure 1 and 2) confirming that the spatiotemporal
distribution of zfPGRN-A is consistent with a role in
the development of MNs. zfPGRN-A generated in the
somatic boundary may provide a paracrine stimulus for
MN development, while intrinsic MN expression of
zfPGRN-A may serve an autocrine function. The extent
to which either PGRN containing compartment, namely
the MNs and the somatic boundary contribute to MN
development and whether they serve distinct or overlap-
ping functions in the developmental process remains
unclear at present.
The developing zebrafish MN provides a very advan-
tageous system to study the ontogeny of individual ver-
tebrate neurons in vivo and in real time. Primary MNs
initiate a common pathway shared by all three classes
of primary motoneuron to a “choice point” where the
growth cones pause when they contact a group of spe-
cialized cells called muscle pioneers at the horizontal
Figure 4 zfPGRN-A knockdown results in disrupted
development of multiple neural structures. Lateral views of
whole-mount embryos probed with islet 1 at 36 hpf. (A), uninjected
embryos (B) embryos injected with zfPGRN-A MO2 (C) embryos
injected with 100 pg zfPGRN-A mRNA, or (D) embryos co-injected
with zfPGRN-A MO2 + 100 pg zfPGRN-A. 96% (48/50) of uninjected
embryos (A) and 90% (45/50) of embryos injected with 100 pg
zfPGRN-A mRNA (B) showed islet1 expression in the developing
hypothalamus, retinal ganglia, sensary ganglia and pharyngeal
arches. 84%(31/37) of embryos injected with 10 ng of zfPGRN-A
MO2 (C) showed disrupted development of multiple neural
structures. Co-injection of embryos with 10 ng MO2 and 100 pg
zfPGRN-A mRNA (D) resulted in the rescue of 80% (40/50) embryos
displaying islet 1 positive neural populations. Scale Bar = 100 μm
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dashed horizontal line in the lateral views of zebrafish
embryos shown in Figures 5, 7 and 9. After pausing,
each growth cone, in turn, selects a different pathway
that leads to a specific population of muscle cells. The
CaP growth cones continue to grow in a ventral direc-
tion. Development of CaP neurons were examined in
whole-mount embryos 26-28 hpf and visualized by
immunostaining using the MN marker znp1. Experi-
ments were designed to test the consequences of 1)
zfPGRN-A over-expression 2) zfPGRN-A knockdown
and 3) rescue of zfPGRN-A knockdown by zfPGRN-A
mRNA. In addition the ability of human PGRN
(hPGRN) mRNA to reproduce the actions of zfPGRN-
A was tested. Rescue experiments involved the co-
injection zfPGRN-A MO2 together with zfPGRN-A
mRNA or hPGRN mRNA. Since the UTR sequence
adjacent to the initiator AUG that is targeted by the
MO is absent from the exogenous zfPGRN-A mRNA,
translation of the injected mRNA is unaffected by the
co-injected MO. To control for the appearance of
developmental defects potentially resulting from the
injection and expression of exogenous protein and the
associated experimental manipulations, mRNA encod-
ing GFP was injected into embryos at the 1-2 cell
stage. The expression of GFP fluorescence was fol-
lowed (Additional File 1). At 24 hpf no gross develop-
mental changes were observed and importantly the
GFP was widely expressed suggesting that all pertinent
tissues and cells are impacted when undertaking
mRNA over-expression and rescue experiments.
Knockdown of zfPGRN-A generated truncation of CaP
neurons indicative of a role in the formation of MNs.
Co-injection of zfPGRN-A or hPGRN mRNA with
zfPGRN-A MO2 resulted in a partial rescue (Figures 5
and 6). Wild type development of CaP neurons shows
branching only beyond the horizontal myoseptum, how-
ever over-expression of zfPGRN-A or hPGRN increased
branching both before and beyond the horizontal myo-
septum. Since ectopic expression of injected mRNA is
ubiquitous (Additional File 1) this may reflect the loss
of topographical specificity in PGRN stimulation of the
developing MN. The disruption of MN structures
caused by depleting zfPGRN-A translation is paralleled
by changes in gross motility in which the touch
response remains intact but touch-evoked swimming is
greatly impaired (Additional File 2, Supplementary
T a b l eS 1 ;A d d i t i o n a lF i l e s3 ,4 ,5 ,6 ,S u p p l e m e n t a r y
Videos 1-4). The motility defect was partially rescued
when the embryos were co-injected with either
zfPGRN-A or hPGRN together with the zfPGRN-A MO.
(Additional File 2, Supplementary Table S1, Additional
Files 7 and 8, Supplementary Videos 5 and 6). These
r e s u l t si m p l y( i )t h a tP G R Ni sr e q u i r e df o rn o r m a lM N
development (ii) that PGRN stimulates neuronal branch-
ing in vivo and that (iii) in this context zfPGRN and
hPGRN are functionally equivalent. These results do not
establish whether PGRN acts directly on the MNs or
Figure 5 Progranulin modulates motoneuron development in vivo: zfPGRN-A knockdown induced CaP MN defects that were partially
rescued by either zfPGRN-A or hPGRN mRNA. Lateral views (anterior to the left; dorsal to the top) of embryos labelled with znp1 mAb at 27 hpf
in (A) wild type embryos, (B) embryos injected with Control MO, (C) 100 pg zfPGRN-A mRNA, (D) 100 pg hPGRN mRNA, (E) zfPGRN-A MO1, (F)
zfPGRN-A MO2, (G) zfPGRN-A MO2+100 pg zfPGRN-A mRNA and (H) zfPGRN-A MO2+100 pg hPGRN mRNA. Observed phenotypes were normal
MN development (A, B), increase in branched axons (C-H), truncation of axons (E, F) and partial rescue of truncated MNs (G, H). Dashed lines
represent horizontal myoseptum. Abbreviations: T-truncation; B-Branching. Scale Bar = 50 μm.
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ment indirectly. A definitive answer to this question will
require a better understanding of the distribution and
properties of PGRN receptors. However, over-expression
of PGRN promotes neurite-like extensions in monocul-
tures of MNs and MN cell lines under highly defined
conditions and suggests a direct effect of PGRN upon
the developing MN [29,30].
Interestingly, unlike the zebrafish, the knockout of
GRN in mice does not result in marked MN defects
[ 4 4 ] .T h i si sp e r h a p ss u r p r i s i n gg i v e nt h ea b u n d a n t
expression of PGRN in murine MNs, its ability to regu-
late neurite extension and survival in murine MN cells
in culture [29,30], the association of GRN mutations
with amyotrophic lateral sclerosis as a putative suscept-
ibility factor [45] and the results obtained in the zebra-
fish model reported in the present study. We suspect
that this implies the existence of highly redundant survi-
val mechanisms with respect to mammalian MNs which
in comparison with the zebrafish counterparts are both
exceptionally elongated and long-lived.
Since these results indicate a novel role of zfPGRN-A
in spinal cord MN development and branching we
investigated whether zfPGRN-A would interact with
other factors that are known to regulate MN develop-
ment. zfPGRN-A mRNA expression reversed the trunca-
tion defects brought about by smn1 knockdown in vivo.
Intriguingly TDP-43 and SMN are both involved with
RNA processing or stabilization. That PGRN is asso-
ciated biologically with both TDP-43 [13] and smn1
(Figure 7, 8) may indicate shared pathways in their
respective pathologies. It is noteworthy that the deple-
tion of zfPGRN-A, snm1, as reported here and TDP-43
as reported elsewhere [46] results in a very similar MN
phenotype namely truncation with excess branching.
Knockdown of NRP-1a, a semaphorin co-receptor
involved in neuronal pathfinding, resulted in multiple
exits and misplaced MNs but not their truncation and
this spectrum of defects was not reversible by co-expres-
sion of zfPGRN-A. The excessive branching seen follow-
ing the depletion of smn1 or NRP-1a was significantly
exaggerated in the presence of co-injected zfPGRN-A
mRNA providing further evidence for the ability of
Figure 6 Progranulin knockdown and over-expression
validation: Average number of Truncated (A) and Branched (B) CaP
MNs (n≥50/group). Values were expressed as mean ± standard error
of the mean. Statistical analyses were done with one-way ANOVA
followed by student-Newman-keuls Multiple Comparisons Test (p <
0.001-***, p < 0.01-**, p < 0.05-*). Error bars represent s.e.m.
Abbreviations: WT, wild type; Control-MO, Control Morpholino;
zfPGRN-A, zebrafish PGRN-A mRNA; hPGRN, human progranulin;
MO1, Morpholino directed against the initiator codon ATG; MO2,
Morpholino directed against the 5’UTR.
Figure 7 Progranulin protects CaP MNs in a model of Spinal Muscular Atrophy SMA): zfPGRN-A mRNA co-injection partially rescues SMN-
MO induced CaP MN defects. (A, B) Lateral views of embryos injected with 9 ng SMN-MO and (C) embryos co-injected with 9 ng SMN-MO +
100 pg zfPGRN-A mRNA. Symbols as in Figure 1. Truncated (A) and branched (B) neurons were observed upon injection of SMN MO while co-
injection with zfPGRN-A rescued truncation (white arrow) and increased axon branching (C). Abbreviations: T-truncation; B-Branching. Scale Bar =
50 μm.
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Page 8 of 13zfPGRN-A to promote MN branching in the zebrafish
CaP developmental model.
Conclusions
PGRN regulates spinal cord MN development and
branching. PGRN is expressed within the zebrafish CaP
motoneuron during development. PGRN knockdown
generates both truncated CaP MNs and premature
branching while ectopic over-expression promotes
branching. zfPGRN-A mRNA rescues truncation defects
in vivo. Consistent with the emerging appreciation of
the neuroprotective properties of PGRN [29,30],
zfPGRN-A over-expression reverses the truncation effect
of SMN knockdown, mutations of which cause SMA in
humans. This study presents the first in vivo demonstra-
tion of the neurotrophic properties of PGRN and
suggests possible future roles in the therapy of neurode-
generative conditions.
Materials and methods
Fish husbandry
Wild type zebrafish were purchased from Aquatica Tro-
picals (Florida) and maintained on a 14 h/10 h light/
dark cycle at 28.5°C in a laboratory aquarium (Allen-
town Caging Equipment Co. Inc., Allentown, NJ). Zeb-
rafish were maintained according to protocols approved
by McGill University animal Care Committee (Protocol
Number 3935). Fish were fed twice daily. In the late
afternoon of the day before embryos are required
(approximately 3:00 p.m.), fish were transferred to a net
positioned towards the top of a holding tank and cov-
ered. In the morning, after the light cycle begins and
Figure 8 Validation of rescue effect of zfPGRN-A in SMA model: Average number of specified MN defects per affected side (n ≥ 50/group).
Statistical analyses were performed with one-way ANOVA followed by student-Newman-keuls Multiple Comparisons Test (p < 0.001-***, p <
0.01-**, p < 0.05-*). Error bars represent s.e.m. Abbreviations: WT, wild type; zfPGRN-A, zebrafish PGRN-A mRNA; smn1-MO-co-injection of
Morpholino directed against initiator ATG and Morpholino directed against 5’UTR.
Figure 9 Co-injection of zfPGRN-A mRNA exaggerated NRP1a-MO induced Cap MN defects particularly branching.( A ,B )E m b r y o s
injected with NRP1a-MO and (C) co-injected with NRP1a-MO + 100 pg zfPGRN-A. Multiple exits (A, C), Branched motor axons (B and C), and
displaced neurons (B, C) were observed. Abbreviations: ME, Multiple Exits; DN, Displaced Neurons; B, Branching. Scale Bar = 50 μm.
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Page 9 of 13spawning has stopped, the eggs that have fallen through
the net were collected from the bottom of the tank.
Embryos to be used for developmental studies were col-
lected and staged by hours post fertilization (hpf) [47].
Whole-mount zebrafish In situ hybridization
Analysis of gene expression by ISH was carried out
essentially as previously described [32] using zfPGRN-A
and Islet 1 sense and anti-sense DIG-labelled riboprobes.
Stained whole-mount embryos were mounted in glycerol
and visualized under a Leica MZFLIII stereomicroscope.
Pictures were taken with a Leica DC350F camera and
processed with Adobe Photoshop 7.0 software.
Embryo microinjection of morpholino oligonucleotides
Morpholino oligonucleotides (MO) were obtained from
Gene Tools, Inc. (Philomath, OR) and diluted in
Danieaux buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM
MgSO4, 0.6 mM Ca(NO3)2, 5.0 mM Hepes pH 7.6)
containing 0.05% phenol red [48]. Approximately 2 nL
of Morpholino along with 0.05% FITC-dextran (Sigma-
Aldrich, Oakville, ON, Canada) was injected into the
yolk of 1- to 2-cell stage embryos using a PLI-100
microinjection system (Harvard Apparatus, St. Laurent,
QC, Canada). Phenotype observation and documenta-
tion were accomplished using a Leica DC300F digital
camera connected to a Leica MZFLIII stereomicroscope
and processed with Adobe Photoshop 7.0 software. The
sequence of MO directed against the initiator AUG of
zfPGRN-A (MO1) was 5′GAGGCAGACTGTCAGT
CTCAACATT3′ and the sequence of the MO corre-
sponding to the 5′UTR region of zfPGRN-A (MO2) was
5′GAGCAGGTGGATTTGTGAACAGCGG3′.T h e
sequence of the MO corresponding to the 5′UTR region
of zfPGRN-B was 5′ TACAGATGAAAAGCCATGAAC-
GACT3′. MOs directed against the initiator AUG of
smn1 (5′CGACATCTTCTGCACCATTGGC3′), the
UTR sequences of smn1 (5′TTTAAATATTTCC-
CAAGTCCAACGT3′)a n dN R P 1 a( 5 ′GAATCCTG-
GAGTTCGGAGTGCGGAA3′) were also used. For
Morpholino injection 10 ng zfPGRN-A, 9 ng of smn1
(both the MOs together) or 8 ng of NRP1a were used.
Microinjection of PGRN mRNA
For zfPGRN-A mRNA over-expression and rescue
experiments a full-length zfPGRN-A/pcDNA3 vector
was generated as follows: The full-length zfPGRN-A
sequence was purchased from RZPD (Berlin, Germany)
as clone UCDMp574E2318Q2 and subcloned into
pcDNA3.1-V5/His vector (Invitrogen, Carlsbad, CA)
u s i n gaf o r w a r dp r i m e rt h a to v e r l a p p e dw i t ht h es t a r t e r
AUG and a reverse primer that read through the termi-
nation codon. The final vector construct consisted of
full-length zfPGRN-A with a carboxyl-terminal tag
consisting of the V5 epitope and 6×Histidine. The
authenticity of the construct was verified by DNA
sequencing. Other vectors used were full-length
hPGRN/pcDNA3
7and GFP/pcDNA3 (Invirogen). For the
zfPGRN-A rescue experiments the MO directed against
the 5′UTR region of zfPGRN-A (MO2). The construct
for mRNA microinjection does not contain the untrans-
lated 5′ sequence of zfPGRN-A. Hence there is no possi-
bility of binding between mRNA and the morpholino
when they are co-injected. Translation enhanced capped
mRNA was synthesized with the mMessage mMachine
Kit (Ambion, Huntingdon, England). For mRNA overex-
pression and rescue experiments 100 pg of either
zfPGRN-A or hPGRN mRNA was used. Microinjection
of a 1 ng of GFP mRNA was used as a control to
demonstrate that the microinjection and over-expression
does not inherently affect development. GFP/pcDNA3
vector was first transcribed and injected up to 1 ng per
embryo and the GFP signal was observed with the
enhanced GFP filter using a Leica MZFLIII stereomicro-
scope. The fluorescent GFP signal was observed uni-
formly throughout the body confirming that the mRNA
was intact and translated into protein.
Immunohistochemistry/immunofluorescence
Embryos (approximately 24 hpf) grown in egg water (water
made from commercially available salt solution, 0.6%
Instant Ocean) were supplemented with 0.003% phenylthio-
carbamide (PTC) to prevent the appearance of melanin pig-
mentation. Staged embryos were manually dechorionated
and fixed for 2 hours at room temperature or overnight at
4°C in 4% paraformaldehyde (PFA)/Phosphate Buffered sal-
ine (PBS). After several washes in PBS, embryos were stored
in 100% methanol until required. Rehydration of embryos
was performed for 5 min periods in successive solutions of
Methanol/PBS with Tween (PBST) and then 3 times in
PBST. Embryos were permeabilized with proteinase K
diluted in PBST at a final concentration of 10 μg/ml. Post
fixation was then carried out in 4% PFA/PBS for 20 min at
room temperature followed by 3 rinses in PBST. Embryos
were incubated with blocking buffer (5% Calf Serum, 1%
DMSO in PBST) for 3-5 hours. Embryos were then incu-
bated with znp1 (ZIRC) monoclonal antibody (1:200), a
marker for motor neurons (MNs), Spinal cord, retinal and
hindbrain axons or zfPGRN-A polyclonal antibody raised
against a synthetic peptide corresponding to residues 242 to
256 of zfPGRN-A (RAEWEDHKQKKPETQC; synthesized
by solid-phase chemistry at the Sheldon Biotechnology
Centre of McGill University with a carboxyl-terminal
cysteine to facilitate conjugation) which was diluted 1:500
in blocking buffer. Incubations were carried out overnight
at 4°C followed by six washes in PBST. Embryos incubated
with anti-znp1 were then treated with Goat anti-Mouse AP
conjugate (Calbiochem) secondary antibody diluted to
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perature. Embryos incubated with anti-zfPGRN-A were
then incubated with Alexa488 conjugated anti-rabbit anti-
body diluted to 1:1000 with blocking buffer in PBST for 2
hr at room temperature. Embryos incubated with both the
secondary antibodies were washed six times in PBST.
Embryos destined to be used to visualize znp1 labelling
were incubated in staining buffer (100 mM Tris-HCl pH
9.5, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween-20,1 mM
levamisol) and colour developed with NBT and BCIP-T
(Fermentas). After 30 min the staining reaction was stopped
and Caudal primary motor neurons (Cap MNs) within the
trunk (excluding the tail region) of the embryos were visua-
lized under an Olympus inverted phase contrast micro-
scope. Pictures were taken with an Olympus DP12 camera
a n dp r o c e s s e dw i t hA d o b eP h o t o s h o p7 . 0s o f t w a r e .T h e
zfPGRN-A immunofluorescence was visualized with a Leica
MZ FLIII stereomicroscope equipped with a GFP filter,
photographed and processed with Adobe Photoshop 7.0
software.
Analysis of Caudal Primary Motoneurons (CaP MNs)
Caudal primary motor axons in whole-mounted 26-28
hpf embryos labelled with Znp1 monoclonal antibody
were analyzed. Only the trunk CaP MNs (12 pairs) were
scored [36]. In wild type embryos all of these had grown
beyond the ventral edge of the notochord into the ven-
tral somite at 24 hpf. Trunk hemisegments were scored
as ‘branched’ when nerves were branched at or above
the ventral edge of the notochord. This strategy was
employed to exclude naturally occurring branching that
is sometimes observed ventral to the notochord. Trunk
hemisegments were also scored as ‘truncated’ when
nerves did not grow beyond the horizontal myoseptum.
When more than one znp1 immunolabeled axon fascicle
exited the spinal cord this was scored as a multiple exit.
Embryos were counted with respect to how many of the
nerves of the 12 pairs in each demonstrated a particular
defect. For each treatment at least three experiments
were performed and at least 50 embryos were scored
per determination. Values were expressed as mean ±
standard error of the mean.
Statistics
Statistical significance among experimental groups was
determined by one-way analysis of variance (ANOVA),
followed by the Newman-Keuls multiple comparison
test. Error bars represent s.e.m. Calculation was per-
formed using GraphPad software (GraphPad Software
Inc., San Diego, CA).
Western blot of Zebrafish Embryos
At 24 hpf embryos were manually de-yolked and fro-
z e ni nl i q u i dn i t r o g e nt h e ns t o r e da t- 8 0 C .S a m p l e s
were thawed and 30 uL of 2× Laemmli buffer was
added and extracts boiled for 5 minutes. Embryo
extracts were resolved on 10% acrylamide gels as 2
embryo equivalents per lane and transferred to nitro-
cellulose membrane. The blots were incubated in
PBST with 1:4000 anti-zfPGRN-A or 1:10000 anti-
hPGRN (R&D System) or 1:1000 anti-GFP (Open Bio-
systems) for 1 hour followed by extensive washing.
After incubating with an anti-rabbit or anti-goat IgG-
horseradish peroxidase (HRP)-conjugated secondary
antibody (diluted 1:4,000) at room temperature for 1
hour blots were visualized using enhanced chemilumi-
nescence (GE Healthcare) according to the manufac-
turer’s instructions. Equivalence of protein loading per
lane was determined by staining with mouse monoclo-
nal b-actin antibody (AC-40; Sigma) at a dilution of
1:1000 followed by 1:4000 anti-mouse IgG-horseradish
peroxidase (HRP)-conjugated secondary antibody. The
rabbit polyclonal anti-zfPGRN-A was raised against
synthetic peptide corresponding to residues 242 to 256
of zfPGRN-A (RAEWEDHKQKKPETQC), and residues
153 to 173 of zebrafish progranulin-B (CGSSPFL
RKFAARRRKPLEKNA), respectively (Sheldon Biotech-
nology Centre). Epitope-specific immunoglobulin was
purified by affinity chromatography. The specificity of
western blot immunoreactive bands were confirmed by
blocking incubations with synthetic zfPGRN-A and
zfPGRN-B peptides.
Additional material
Additional file 1: In vivo translation of 1 ng gfp mRNA. (A) bright
field image showing no developmental abnormalities and (B) widespread
appearance of gfp signal within the developing embryo at 27 hpf.
Additional file 2: Supplementary Table S1: Summary of the survival
and swimming behaviour of embryos shown in videos 1-11
(Additional Files 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13).
Additional file 3: Video 1: Touch-evoked swimming behaviour of
wild-type embryo at 48 hpf.
Additional file 4: Video 2: Reduced motility of zfPGRN-A deficient
embryos to swim away when compared to wild-type embryos at 48
hpf.
Additional file 5: Video 3: Touch-evoked swimming behaviour of
wild-type embryo at 72 hpf.
Additional file 6: Video 4: Inability of zfPGRN-A deficient embryos
to swim away when compared to wild-type embryos at 72 hpf.
Additional file 7: Video 5: Embryos co-injected with zfPGRN-A
mRNA together with PGRN-A MO show rescued motility (48 hpf).
Additional file 8: Video 6: Embryos co-injected with hPGRN mRNA
together with PGRN-A MO show rescued motility (48 hpf).
Additional file 9: Video 7: Embryos over-expressing zfPGRN-A show
a strong avoidance swimming behaviour (48 hpf).
Additional file 10: Video 8: Embryos over-expressing hPGRN show a
strong avoidance swimming behaviour (48 hpf).
Additional file 11: Video 9: smn1 knockdown embryos do not show
the strong avoidance swimming phenotype typical of wild-type
larvae (48 hpf).
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Page 11 of 13Additional file 12: Video 10: Smn1 knockdown embryos co-injected
with zfPGRN-A mRNA show an improved avoidance swimming
phenotype when compared to that resulting from knockdown of
smn1 (48 hpf).
Additional file 13: Video 11: Smn1 knockdown embryos co-injected
with hPGRN mRNA show an improved avoidance swimming
phenotype when compared to that resulting from knockdown of
smn1 (48 hpf).
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